These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

568 related articles for article (PubMed ID: 35069526)

  • 1. Diet and Hygiene in Modulating Autoimmunity During the Pandemic Era.
    Abdelhamid L; Luo XM
    Front Immunol; 2021; 12():749774. PubMed ID: 35069526
    [TBL] [Abstract][Full Text] [Related]  

  • 2. COVID-19, rheumatic diseases and immune dysregulation-a perspective.
    Tariq S; Van Eeden C; Tervaert JWC; Osman MS
    Clin Rheumatol; 2021 Feb; 40(2):433-442. PubMed ID: 33411143
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Changes in Dietary Patterns and Clinical Health Outcomes in Different Countries during the SARS-CoV-2 Pandemic.
    Filip R; Anchidin-Norocel L; Gheorghita R; Savage WK; Dimian M
    Nutrients; 2021 Oct; 13(10):. PubMed ID: 34684615
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Autoimmune complications of COVID-19.
    Yazdanpanah N; Rezaei N
    J Med Virol; 2022 Jan; 94(1):54-62. PubMed ID: 34427929
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adaptive Immunity and the Risk of Autoreactivity in COVID-19.
    Moody R; Wilson K; Flanagan KL; Jaworowski A; Plebanski M
    Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445670
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The SARS-CoV-2 as an instrumental trigger of autoimmunity.
    Dotan A; Muller S; Kanduc D; David P; Halpert G; Shoenfeld Y
    Autoimmun Rev; 2021 Apr; 20(4):102792. PubMed ID: 33610751
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immune characterization and profiles of SARS-CoV-2 infected patients reveals potential host therapeutic targets and SARS-CoV-2 oncogenesis mechanism.
    Policard M; Jain S; Rego S; Dakshanamurthy S
    Virus Res; 2021 Aug; 301():198464. PubMed ID: 34058265
    [TBL] [Abstract][Full Text] [Related]  

  • 8. De novo lupus nephritis after SARS-CoV-2 infection.
    Mok CC; Chu CS; Tse SM
    Lupus; 2023 Jun; 32(7):893-899. PubMed ID: 37173871
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The mosaic of autoimmunity - A taste for more. The 12th international congress of autoimmunity 2021 (AUTO12) virtual.
    Mahroum N; Zoubi M; Lavine N; Ohayon A; Amital H; Shoenfeld Y
    Autoimmun Rev; 2021 Nov; 20(11):102945. PubMed ID: 34509655
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interferons and other cytokines, genetics and beyond in COVID-19 and autoimmunity.
    Opdenakker G; Van Damme J
    Cytokine Growth Factor Rev; 2021 Apr; 58():134-140. PubMed ID: 33563543
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SARS-CoV-2 infection as a trigger of autoimmune response.
    Sacchi MC; Tamiazzo S; Stobbione P; Agatea L; De Gaspari P; Stecca A; Lauritano EC; Roveta A; Tozzoli R; Guaschino R; Bonometti R
    Clin Transl Sci; 2021 May; 14(3):898-907. PubMed ID: 33306235
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Autoimmunity and COVID-19 - The microbiotal connection.
    Katz-Agranov N; Zandman-Goddard G
    Autoimmun Rev; 2021 Aug; 20(8):102865. PubMed ID: 34118455
    [TBL] [Abstract][Full Text] [Related]  

  • 13. COVID-19 and autoimmune bullous diseases: Lessons learned.
    Kasperkiewicz M; Woodley DT
    Autoimmun Rev; 2023 Apr; 22(4):103286. PubMed ID: 36738951
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Does autoimmune vitiligo protect against COVID-19 disease?
    Post NF; Luiten RM; Wolkerstorfer A; Bekkenk MW; Böhm M
    Exp Dermatol; 2021 Sep; 30(9):1254-1257. PubMed ID: 34081788
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Insights into new-onset autoimmune diseases after COVID-19 vaccination.
    Guo M; Liu X; Chen X; Li Q
    Autoimmun Rev; 2023 Jul; 22(7):103340. PubMed ID: 37075917
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhanced Expression of Autoantigens During SARS-CoV-2 Viral Infection.
    Saheb Sharif-Askari N; Saheb Sharif-Askari F; Ahmed SBM; Hannawi S; Hamoudi R; Hamid Q; Halwani R
    Front Immunol; 2021; 12():686462. PubMed ID: 34276672
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular mimicry, hyperactive immune system, and SARS-COV-2 are three prerequisites of the autoimmune disease triangle following COVID-19 infection.
    Vahabi M; Ghazanfari T; Sepehrnia S
    Int Immunopharmacol; 2022 Nov; 112():109183. PubMed ID: 36182877
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SARS-CoV-2 triggering autoimmune diseases.
    Mobasheri L; Nasirpour MH; Masoumi E; Azarnaminy AF; Jafari M; Esmaeili SA
    Cytokine; 2022 Jun; 154():155873. PubMed ID: 35461172
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The triggering of post-COVID-19 autoimmunity phenomena could be associated with both transient immunosuppression and an inappropriate form of immune reconstitution in susceptible individuals.
    Cañas CA
    Med Hypotheses; 2020 Dec; 145():110345. PubMed ID: 33080459
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular mimicry and autoimmunity in the time of COVID-19.
    Rojas M; Herrán M; Ramírez-Santana C; Leung PSC; Anaya JM; Ridgway WM; Gershwin ME
    J Autoimmun; 2023 Sep; 139():103070. PubMed ID: 37390745
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.